Any new, rapidly changing, irregular, bleeding, or symptomatic pigmented lesion should be evaluated by a dermatologist
One of the primary ways GLP-1 agonists work is by reducing appetite, meaning people eat less and, unsurprisingly, lose weight
Patient-specific 503A compounding may continue to be available under narrow circumstances, specifically when there is a documented clinical reason a commercially available product cannot be used for that individual patient
Jody Dushay, M.D., MMSc, is an endocrinologist at the Beth Israel Deaconess Medical Center and assistant professor of medicine at Harvard Medical School
We often treat patients with type 2 diabetes and those who are having difficulty controlling their weight
A thorough medical evaluation is necessary before beginning therapy